Valneva SE (VLA.PA) Stock Price
€3.88 4.9%
to add to portfolio
AI Score

-
Alternative
3 -
Fundamental
5 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Valneva SE, AI stock picks, stock alerts and much more.
VLA.PA AI Stock Analysis
AI stock analysis for VLA.PA is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Valneva SE (VLA.PA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Valneva SE (VLA.PA) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Valneva SE (VLA.PA), currently trading at €3.88, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About VLA.PA

-
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.
-
Symbol
VLA.PA
-
Market
EURONEXT
-
Industry
Biotechnology
-
Market Cap
613.5M
Similar Stocks
![]() |
Financière de Tubize SA TUB.BR |
€154 0.1% |
5 |
![]() |
OSE Immunotherapeutics SA OSE.PA |
€7.07 4.1% |
4 |
![]() |
UCB SA UCB.BR |
€189.8 0.2% |
7 |
![]() |
Innate Pharma S.A. IPH.PA |
€1.9 1.1% |
2 |
![]() |
Pharming Group PHARM.AS |
€0.8375 0.5% |
5 |
News
No news articles.
VLA.PA Alternative Data
Web Traffic
Valneva SE receives an estimated 42143 monthly visitors to valneva.com, which is down by -8.3% over the last month.
-
Web Traffic
42143
-
Change from Previous Month
8.3%
-
3 Month Change
10.4%
News Mentions
Valneva SE was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Valneva SE has 8,159 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.5% over the last month.
-
Twitter Followers
8159
-
Daily Change
0%
-
1 Month Change
0.5%
-
3 Month Change
1.6%
Facebook Engagement
Valneva SE has engaged 18 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
18
-
Daily Change
62.5%
-
1 Month Change
38.5%
-
3 Month Change
50%
Instagram Followers
Valneva SE has 235 Instagram Followers on its main Instagram account, up by 4% over the last month.
-
Instagram Followers
235
-
Daily Change
2.2%
-
1 Month Change
4%
-
3 Month Change
9.3%
Youtube Subscribers
Valneva SE has 675 subscribers on its main Youtube channel, up by 0.3% over the last month.
-
Youtube Subscribers
675
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
0%
LinkedIn Followers
42,937 are following Valneva SE on LinkedIn, up by 3.5% over the last month.
-
LinkedIn Followers
42937
-
Daily Change
0.1%
-
1 Month Change
3.5%
-
3 Month Change
9.9%
Job Postings
Valneva SE has an estimated 10 open job postings, which is down -37.5% over the last month.
-
Job Postings
10
-
Daily Change
11.1%
-
1 Month Change
37.5%
-
3 Month Change
70.6%
LinkedIn Employees
According to LinkedIn, Valneva SE has 670 employees, up by 1.2% over the last month.
-
LinkedIn Employees
670
-
Daily Change
0%
-
1 Month Change
1.2%
-
3 Month Change
2.3%
Business Outlook
-
Business Outlook
22
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
VLA.PA Financials
VLA.PA Key Metrics
-
Total Revenue
€45.8M
-
Net Income
-€9.2M
-
Earnings per Share
-€0.0702
-
Free cash flow
-€26.4M
-
EBITDA
-€7.2M
-
EBITDA Ratio
-0.157668
-
Total Assets
€516.6M
VLA.PA 2-year Revenue & Income
VLA.PA 2-year Free Cash Flow
VLA.PA Technicals
VLA.PA SMA
VLA.PA RSI
FAQ
What's the current price of Valneva SE (VLA.PA) Stock?
The price of an Valneva SE (VLA.PA) share is €3.88.
What's the market cap of Valneva SE?
The current market cap of Valneva SE is 613.5M.
Should I buy or sell VLA.PA?
Valneva SE exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Valneva SE a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Valneva SE stock. There are several bearish signals and market challenges that could negatively impact Valneva SE's future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Valneva SE (VLA.PA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Valneva SE stock right now, as the outlook appears bearish.
What are some stocks similar to Valneva SE (VLA.PA) that investors often compare it to?
Valneva SE (VLA.PA) is often compared to similar stocks such as Financière de Tubize SA, OSE Immunotherapeutics SA, UCB SA, Innate Pharma S.A. and Pharming Group.
What is the forecast for Valneva SE's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Valneva SE's stock price to be around €3.48 in 2026. Starting from the current price of €3.88, this represents a 10.4% change in price, indicating a bearish outlook for the stock.
How to buy Valneva SE (VLA.PA) Stock?
Valneva SE stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Valneva SE shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.